Bone Abstracts

Pradaxa (dabigatran etexilate) is a new anticoagulant, which recently has been approved for clinical use. Dabigatran etexilate (DE) is a direct thrombin inhibitor, which in addition to its effect on blood clotting, may have an anabolic effect on bone. Recently, it has been reported that DE could significantly reduce bone resorption and enhance bone formation resulting in a significant and substantial increase in trabecular bone mass in mice.The aim of th...